Nestlé: completes acquisition of Aimmune Therapeutics
(CercleFinance.com) - Nestlé announces having finalised its acquisition of Aimmune Therapeutics, which as a result joins its division Nestlé Health Science (NHSc) as an independent activity.
It will continue to be managed from Brisbane, California.
The Swiss food giant indicated on Tuesday that once the offer of its subsidiary SPN MergerSub is completed, at a price of 34.50 dollars per Aimmune Therapeutics share, it holds approximately 84% of this company.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
It will continue to be managed from Brisbane, California.
The Swiss food giant indicated on Tuesday that once the offer of its subsidiary SPN MergerSub is completed, at a price of 34.50 dollars per Aimmune Therapeutics share, it holds approximately 84% of this company.
Copyright (c) 2020 CercleFinance.com. All rights reserved.